In addition to the direct funding of CARB-X, the BMBF funds the so-called "CARB-X accelerator" on a national level with around EUR 1 million. The CARB-X accelerator is composed of the product development unit (PDU) of the German Center for Infection Research (DZIF), together with the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI). They are at the disposal of applicants and projects for scientific-regulatory questions. Further they advise and accompany researchers on their way to a potential CARB-X funding. BfArM and PEI especially support this process with regard to regulatory questions in the context of scientific consulting events as well as in the implementation of trainings. This project combines different phases: the phase of the discovery of new therapeutic approaches, their pharmaceutical and preclinical development, as well as clinical trials.